Altre lingue NovaBay Pharmaceuticals, Inc.

Azioni

NBY

US66987P4090

Mercato chiuso - Nyse Altri mercati azionari 22:00:00 10/06/2024			Variaz. 5gg	Var. 1 gen.
2,82 ^USD	+4,06%		-10,48%	-60,50%

09/05	NovaBay Pharmaceuticals, Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
09/05	Transcript : NovaBay Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 09, 2024

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

NovaBay Pharmaceuticals Plan of Compliance Accepted by the NYSE American	07/06
NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates	29/05
NovaBay Pharmaceuticals Launches Avenova Product Bundles for Individualized Relief from Multifactorial Dry Eye Symptoms	13/05
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Reports Q1 Revenue $2.63M, vs. Street Est of $3.28M	09/05
NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results	09/05
NovaBay Pharmaceuticals Announces Record Ordered Product Sales of Avenova-Branded Products in April through Amazon	07/05
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024	06/05
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024	03/05
NovaBay Pharmaceuticals Announces New and Enhanced Direct-to-Consumer Marketing to Efficiently Engage Customers and Drive Avenova Sales	22/04
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity	20/04
NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses	17/04
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Earnings Flash (NBY) NOVABAY PHARMACEUTICALS Posts Q4 Revenue $3.7M, vs. Street Est of $3.4M	26/03
NovaBay Pharmaceuticals Reports 2023 Fourth Quarter and Full Year Financial Results	26/03
NovaBay Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/03
NovaBay Pharmaceuticals : Acquisition/Asset Disposal - Form 8-K	26/03
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024	25/03
New Age Investments LLC completed the acquisition of DERMAdoctor, Inc. from NovaBay Pharmaceuticals, Inc..	25/03
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment, Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023	15/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue NovaBay Pharmaceuticals, Inc.

Azioni

NBY

US66987P4090

Altre lingue

Filtri